Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of oncogenic KrasG12D on the expression of inflammation-related genes in myeloid cells

ABSTRACT: Oncogenic Ras mutations occur frequently in hematological malignancies. It was unclear if besides the direct transforming effect via constant RAS/MEK/ERK signaling, an inflammation-related effect of KRAS contributes to the development of the disease. We used microarray-based analysis of murine hematopoietic bone marrow (BM) cells harboring active inducible KrasG12D to reveal the expression of inflammation-related genes.

ORGANISM(S): Mus musculus

PROVIDER: GSE131885 | GEO | 2020/02/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Comparison of KrasG12D/WT;p53Fx/Fx and KrasG12D/G12D;p53Fx/Fx MEFs

2016-02-24 | GSE75871 | GEO

RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

Project description:Experiment designed to study the effect of 1 or 2 copies of deregulated myc on transcriptional profile during pancreatic cancer progression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ mice treated 12 hours with Tamoxifen.

2022-06-08 | E-MTAB-10807 | biostudies-arrayexpress

The effect of oncogenic KrasG12D on the expression of inflammation-related genes in myeloid cells

Project description:The effect of oncogenic KrasG12D on the expression of inflammation-related genes in myeloid cells

| PRJNA545239 | ENA

KRAS K104 modification affects KRASG12D-GEF interaction and mediated cell growth and motility

Project description:Mutant RAS genes play an important role in regulating tumors through lysine residue 104 to impair GEF-induced nucleotide exchange, but the regulatory role of KRAS K104 modification on the KRASG12D mutant is not yet clear. We found that KRASG12D/K104Q decreased the bind to RBD of Raf1 and also decreased cell growth, invasion and migration as well as whole-genome cDNA microarray found that KRASG12D/K104Q decrease the expression of NPIPA2, DUSP1 and IL6 in lung and ovarian cancer cells. This study clear implicates computational and experimental studies involving Lys104 of KRASG12D and GEF and provides a target for the analysis of future treatments.

2020-09-19 | GSE158235 | GEO

Comparison of KrasG12D/WT;p53Fx/Fx and KrasG12D/G12D;p53Fx/Fx MEFs

Project description:Microarray expression data generated to compare the biological impact of KrasG12D allelic duplication in p53null mouse embryonic fibroblasts (MEFs). The RAS/MAPK-signalling pathway is frequently deregulated in non-small cell lung cancer (NSCLC), often through activating mutations in KRAS. Mouse models demonstrated that activation of a single endogenous mutant Kras allele is sufficient to promote lung tumour formation, but acquisition of other genetic alterations is required for malignant progression. Using a well-established lung cancer mouse model we recently demonstrated that advanced KrasG12D-driven spontaneous tumours frequently exhibit enhanced MAPK signalling and KrasG12D allelic enrichment (KrasG12D/Kraswild-type>1), implying that mutant Kras copy gains are positively selected during lung cancer progression. To compare the oncogenic impact of a single mutant allele versus additional mutant Kras copy gain, we carried out a comprehensive analysis of mutant Kras homozygous and heterozygous MEFs and lung cancer cells and show that these genotypes are phenotypically distinct. Title: Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities Authors: Emma M Kerr, Edoardo Gaude, Frances K Turrell, Christian Frezza and Carla P Martins For MEF generation, KrasLSL-G12D/+ ;p53Fx/Fx mixed background (C57Bl/6/129/Sv) animals were interbred and embryos collected at day E12.5 to overcome KrasLSL-G12D/G12D embryonic lethality and Cre-mediated recombination performed immediately after MEF generation. Cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-Glutamine for one passage and then infected with adenovirus-Cre (5âÃâ107âplaque-forming units/1 x 106 cells). Recombination of LoxP sites was confirmed by PCR analysis. Three independent embryos per genotype were analysed using GPL6887 Illumina MouseWG-6 v2.0 expression beadchip.

2016-02-24 | E-GEOD-75871 | biostudies-arrayexpress

Transcription profiling of pancreata from wild type, KrasG12D, Ela-Tgfa and KrasG12D Ela-Tgfa mice

Project description:Transcription profiling by array of pancreas from KrasG12D, Ela-Tgfa and KrasG12D Ela-Tgfa mice

2008-07-23 | E-TABM-304 | biostudies-arrayexpress

Comparison of gene expression changes of pancreatic tissue from Ptf1aCre;KrasG12D and Ptf1aCre;KrasG12D;SnailKI/+ mice

Project description:Comparison of gene expression changes of pancreatic tissue from Ptf1aCre;KrasG12D and Ptf1aCre;KrasG12D;SnailKI/+ mice at the age of 1 month and 3 months.

2022-11-19 | E-MTAB-8174 | biostudies-arrayexpress

An Epigenetic Memory of Inflammation Induces Context-Dependent Lineage Plasticity in the Pancreas with Divergent Phenotypic Outcomes [memory + KrasG12D scRNA-seq]

Project description:An Epigenetic Memory of Inflammation Induces Context-Dependent Lineage Plasticity in the Pancreas with Divergent Phenotypic Outcomes [memory + KrasG12D scRNA-seq]

2023-10-24 | GSE198184 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of pancreatic tissue transcriptomes from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein

Project description:Purpose: we used next generation sequencing to analyze gene expression profiles of pancreatic tissues from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein. The goals of this study are to compare the different gene expression profiles of pancreatic tissue between KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein.

2021-06-11 | GSE176571 | GEO

mTORC1 and mTORC2 converge on the Arp2/3 complex to promote KrasG12D-induced acinar-to-ductal metaplasia and early pancreatic carcinogenesis

Project description:Oncogenic KrasG12D, a driver mutation of pancreatic ductal adenocarcinoma (PDAC), induces neoplastic transformation of acinar cells through acinar-to-ductal metaplasia (ADM). Here, we show that both functional complexes of mTOR (mechanistic target of rapamycin kinase, mTORC1 and mTORC2) are specifically activated in ADM. Murine models uncover that mTORC1 and mTORC2 cooperate to promote KrasG12D-driven ADM development. Proteomic analyses identify Arp2/3 complex, an actin nucleator, as the common downstream effector: mTORC1 is responsible for the protein synthesis of Rac1 and Arp3 while mTORC2 promotes the Arp2/3 complex activity via Akt/Rac1 signalling. Genetic ablation of Arp2/3 complex completely arrests KrasG12D-driven ADM development. The Arp2/3 complex-mediated y-branching of actin network promotes the basolateral spread of filamentous actin, which is indispensable for acinar cells-initiated carcinogenesis. Induced by oncogenic KrasG12D, ADM is a metaplastic phenotype of acinar cells that requires extensive actin rearrangements. mTORC1 and mTORC2, downstream targets of KrasG12D, have well-established oncogenic functions in PDAC development. The actin-related protein 2/3 (Arp2/3) complex is the first identified actin nucleator. Regarded as textbook knowledge, it is activated by EGFR/Rac1 signalling to promote the polymerisation of branched actin filaments from pre-existing filaments in numerous biological contexts. Hereby, we identify that mTORC1 and mTORC2 attain a dual, yet non-redundant, regulatory role in promoting Arp2/3 complex function, which is responsible for generating basolateral filamentous actin in ADM. Thus, the role of Arp2/3 complex fills up the missing gap between putative oncogenic signals and actin dynamics underlying PDAC initiation.

2021-01-07 | PXD018296 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data